[
  {
    "ts": null,
    "headline": "Is Bristol-Myers Squibb Co. (BMY) the Best Stock for 10 Years?",
    "summary": "We recently compiled a list of the Long-Term Stock Portfolio: Best Stocks for 10 Years. In this article, we are going to take a look at where Bristol-Myers Squibb Co. (NYSE:BMY) stands against the other long-term stocks. To select stocks with long-term growth potential, investors should focus on fundamental analysis, evaluating financial health through earnings history, […]",
    "url": "https://finnhub.io/api/news?id=1a2d325c4ffe1c327842be54223532260c8f4693de87ad02494f0f8d7144e88e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735586064,
      "headline": "Is Bristol-Myers Squibb Co. (BMY) the Best Stock for 10 Years?",
      "id": 132204650,
      "image": "https://s.yimg.com/ny/api/res/1.2/ZsrqNB_sdV78LPtS9DZ12A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the Long-Term Stock Portfolio: Best Stocks for 10 Years. In this article, we are going to take a look at where Bristol-Myers Squibb Co. (NYSE:BMY) stands against the other long-term stocks. To select stocks with long-term growth potential, investors should focus on fundamental analysis, evaluating financial health through earnings history, […]",
      "url": "https://finnhub.io/api/news?id=1a2d325c4ffe1c327842be54223532260c8f4693de87ad02494f0f8d7144e88e"
    }
  },
  {
    "ts": null,
    "headline": "Chevron, Kimberly-Clark Among 15 Companies To Announce Dividend Increases In January",
    "summary": "Get the scoop on upcoming dividend increases from companies with long-term growth histories, including modest increases from Chevron and Kimberly-Clark in...",
    "url": "https://finnhub.io/api/news?id=bc456e33e15cf76dcaa8b97d53d4313285e1d1e774bdc8090f51d5d1802a753a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735585359,
      "headline": "Chevron, Kimberly-Clark Among 15 Companies To Announce Dividend Increases In January",
      "id": 132207437,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/459000811/image_459000811.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Get the scoop on upcoming dividend increases from companies with long-term growth histories, including modest increases from Chevron and Kimberly-Clark in...",
      "url": "https://finnhub.io/api/news?id=bc456e33e15cf76dcaa8b97d53d4313285e1d1e774bdc8090f51d5d1802a753a"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves BMS’ Opdivo Qvantig for solid tumour indications",
    "summary": "The approval for Opdivo Qvantig is based on the results from the Phase III CheckMate-67T trial.",
    "url": "https://finnhub.io/api/news?id=217dc2f4dfdaf9cbae8a4f4c18977aa507e6574b40ccab780e2dcc1f749c784f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735565954,
      "headline": "FDA approves BMS’ Opdivo Qvantig for solid tumour indications",
      "id": 132204651,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/BMS_shutterstock_2377348837-1.jpg",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The approval for Opdivo Qvantig is based on the results from the Phase III CheckMate-67T trial.",
      "url": "https://finnhub.io/api/news?id=217dc2f4dfdaf9cbae8a4f4c18977aa507e6574b40ccab780e2dcc1f749c784f"
    }
  },
  {
    "ts": null,
    "headline": "Beaten Down Biogen Stock Looks Attractive At Current Levels",
    "summary": "The Biogen Inc. story of the last 10 years has been one of periods of excitement, followed by significant disappointments. Click here to read I rate BIIB a Buy.",
    "url": "https://finnhub.io/api/news?id=9d2f84f3c5cf32361741ae09e904d063b6c6bf280e774c53c963c02299824733",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735565867,
      "headline": "Beaten Down Biogen Stock Looks Attractive At Current Levels",
      "id": 132204159,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165724853/image_2165724853.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "The Biogen Inc. story of the last 10 years has been one of periods of excitement, followed by significant disappointments. Click here to read I rate BIIB a Buy.",
      "url": "https://finnhub.io/api/news?id=9d2f84f3c5cf32361741ae09e904d063b6c6bf280e774c53c963c02299824733"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval",
    "summary": "Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why I'm bullish on BMY heading into 2025.",
    "url": "https://finnhub.io/api/news?id=f7f10c2fe2df9986c14e4c6587026f43bda98279fb61b89a09331dbcc81ce6ea",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735561817,
      "headline": "Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval",
      "id": 132203613,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1617235960/image_1617235960.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why I'm bullish on BMY heading into 2025.",
      "url": "https://finnhub.io/api/news?id=f7f10c2fe2df9986c14e4c6587026f43bda98279fb61b89a09331dbcc81ce6ea"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb - U.S. Food and Drug Administration Approves Opdivo Qvantig Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo Indications",
    "summary": "PRINCETON - Bristol Myers Squibb today announced that the U.S. Food and Drug Administration granted approval for Opdivo Qvantig injection for subcutaneous use, a combination product of nivolumab...",
    "url": "https://finnhub.io/api/news?id=b8f5c499555a5ad45763433432f032771eb35dde77e9b1e85f9f64664d3dbc13",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735550955,
      "headline": "Bristol Myers Squibb - U.S. Food and Drug Administration Approves Opdivo Qvantig Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo Indications",
      "id": 132202401,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "PRINCETON - Bristol Myers Squibb today announced that the U.S. Food and Drug Administration granted approval for Opdivo Qvantig injection for subcutaneous use, a combination product of nivolumab...",
      "url": "https://finnhub.io/api/news?id=b8f5c499555a5ad45763433432f032771eb35dde77e9b1e85f9f64664d3dbc13"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers: Opdivo Qvantig approved for subcutaneous use",
    "summary": "Bristol Myers Squibb reports that the US FDA has approved its Opdivo Qvantig injection for subcutaneous use in most of Opdivo's previously approved indications for solid tumors in adults.Administered...",
    "url": "https://finnhub.io/api/news?id=40f048980bb7bb3a82b352fbd6c67f2913c7a23b0e38a57d662b50aedcdeed07",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735522093,
      "headline": "Bristol Myers: Opdivo Qvantig approved for subcutaneous use",
      "id": 132200256,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb reports that the US FDA has approved its Opdivo Qvantig injection for subcutaneous use in most of Opdivo's previously approved indications for solid tumors in adults.Administered...",
      "url": "https://finnhub.io/api/news?id=40f048980bb7bb3a82b352fbd6c67f2913c7a23b0e38a57d662b50aedcdeed07"
    }
  }
]